| PIPELINE
Our research and development programs are quite diverse and offer access to a large market potential. We currently have programs in a number of stages of development.
Current Programs
Trypanosomiasis (African Sleeping Sickness/Nagana) - livestock and human
- 25 preclinical candidates demonstrating positive in vitro and in vivo tox results
- estimated potential market size for livestock $250M
- estimated annual economic loss in GDP to Africa: $5 - 10 billion
Leishmaniasis
- 25 preclincial candidates demonstrating positive in vitro and in vivo tox results
- estimated market size: $300M
- human market, 12M infected, 350M at risk
Malaria
- 5 preclinical candidates demonstrating positive in vitro and in vivo tox results
- estimated market size: $500M +
- estimated annual economic cost to Africa: $12 billion
Tuberculosis
- estimated market size: $500-700M (2010)
- 85% of market concentrated in Africa
Close term future programs
Cancer - 35 preclinical candidates showing positive in vitro results
Onchocerciasis (River Blindness) related to above protozoans
Cryptospordia (Biowarfare agent) related to above protozoans
R&D Milestones Achieved
Leishmaniasis
- in vitro efficacy (Testing performed at UBC)
- mouse toxicity in vivo (Testing performed at Makerere University)
- in vitro Human Cellular Toxicity (Testing performed at UBC)
- in vitro efficacy (Testing performed at McGill)
Trypanosomiasis
- in vitro efficacy (Testing performed at UBC)
- mouse toxicity in vivo (Testing performed at Makerere University)
- in vitro Human Cellular Toxicity (Testing performed at UBC)
- in vitro efficacy (Testing performed at McGill)
Malaria
- in vitro efficacy (Testing performed at Alberta ProvLabs)
- mouse toxicity in vivo (Testing performed at Makerere University)
- in vitro Human Cellular Toxicity (Testing performed at UBC)
Our Ongoing R&D Programs
Trypanosomiasis
- Mechanism of Action Study (McGill University) – 5-10 drug
candidates – completed during the first calendar quarter of 2009.
- Mouse in vivo Efficacy Testing (Makerere University) - 25 drug candidates - completed by December 2008
Leishmaniasis
- Mouse in vivo Efficacy Testing (Makerere University) - 25 drug candidates - completed by December 2008
Malaria
- Mouse in vivo Efficacy Testing - 5 drug candidates
- Second wave of compounds for in vitro screening (ProvLabs)
Tuberculosis
- in vitro screening (US National Institute of Allergy and Infectious Disease) - ~250 candidates - completed by January 2009
- Mouse in vivo Efficacy Testing - completed by April 2009
|
